Organization
Guangzhou Lupeng Pharmaceutical Company LTD
9 clinical trials
Clinical trial
A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy SubjectsStatus: Active (not recruiting), Estimated PCD: 2024-12-30
Clinical trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LP-108, a BCL-2 Inhibitor, Combined With Azacitidine In Subjects With AML, MDS, CMMLStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
The Mass Balance Study of [14C]LP-168 in Chinese Healthy SubjectsStatus: Completed, Estimated PCD: 2024-02-02
Clinical trial
A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHLStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LP-168 Following Single and Multiple Oral Administration to Healthy VolunteersStatus: Completed, Estimated PCD: 2022-11-20
Clinical trial
A Randomized, Two-period, Two-sequence Two-treatment Crossover Design Food Effect Study to Evaluate the Pharmacokinetic Profile of LP-168 Tablets in Healthy Subjects After Single Oral Administration Under Fasted and Fed ConditionsStatus: Completed, Estimated PCD: 2023-08-21
Clinical trial
A Phase I Study on Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of LP-118 in Patients With Advanced MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-30
Clinical trial
A Phase 1 Open-Label Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of LP-168 in Adult Patients With Relapse or Refractory B-Cell LymphomaStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
An Open Label, Single Arm, Multicenter Phase II Study of the Efficacy and Safety of LP-168 Monotherapy for Recurrent or Refractory Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-02-28